COH -Cochlear
29/7/26
Links
----------
Cochlear Limited (ASX: COH) is a global medical device leader that has delivered steady revenue growth and robust profits over the last five years, though recent earnings have faced headwinds from softer market demand and upgraded cost guidance, significantly depressing its stock price.
Financial Snapshot
- Market Capitalization: ~A$7.8 billion
- Revenue (TTM): ~A$2.34 billion, representing a compound annual growth rate (CAGR) of over 14% across recent years.
- Profit (TTM): ~A$345 million. The company has generally maintained healthy net profit margins around 14% to 17%.
- Return on Equity (ROE): 18.15%.
Debt Profile & Balance Sheet
- Cochlear maintains a pristine balance sheet characterized by a very low debt-to-equity ratio of just 12.5%.
These are the D/E ratios for the last 5 years:
2026 - 0.13
2025 - 0.12
2024 - 0.13
2023 - 0.12
2022 - 0.15
- It carries minimal long-term debt and generates strong cash flow, putting it in a low-risk position to comfortably cover liabilities.
Performance Trends & Recent Challenges
- 5-Year Profit Trend: From 2021 to mid-2025, Cochlear saw a strong upward trajectory in both profit and EBITDA. However, 1H 2026 net income dropped 21% year-over-year to A$161.5 million due to cost-of-living pressures delaying customer upgrades.
- 2026 Earnings Cut: In April 2026, Cochlear significantly cut its full-year profit guidance (lowering underlying NPAT to A$290-A$330 million) due to soft market growth and higher-than-expected costs, causing a sharp pullback in its share price.
- Dividends: Despite the recent share price volatility, Cochlear has steadily increased its annual dividend payouts every year over the last 5 years (moving from $2.55 to upwards of $4.30 per share).
-----------
ROIC Vs WACC
Over the last 10 years, Cochlear Ltd (ASX:COH) has consistently maintained a Return on Invested Capital (ROIC) well above its Weighted Average Cost of Capital (WACC), demonstrating strong economic value creation. [1]
- ROIC (Return on Invested Capital): Averaged above 30% for most of the past decade, though recent trailing figures have normalized closer to 13%–19% due to shifting post-pandemic operational dynamics and market mix. [1, 2, 3]
- WACC (Weighted Average Cost of Capital): Historically tracked at a 10-year median of around 7.4%–7.6%, though rising broader discount rates have pushed current WACC estimates higher toward 9.5%–10.5%. [1, 2, 3]
- Value Spread (ROIC vs. WACC): Maintained a consistently positive spread across the decade, indicating that Cochlear reliably earns returns higher than the cost of raising its capital. Barring fiscal 2020—when elective surgeries dropped sharply during the pandemic and ROIC compressed close to its WACC—the company's operational efficiency has comfortably outperformed its hurdle rate
.......................
No comments:
Post a Comment